Partnership |
| |
 |
axxonis has
acquired the Technology which guarantees axxonis to
receive and purchase exclusive patent rights and know-how to certain
products. |
|
Alfarma s.r.o., Prague,
Czech Republic |
|
Novosis, Munich: for
development of lisuride TTS and GMP, manufacturer of clinical service
form. |
|
MDS, Munich, for performing
Phase I clinical testing |
|
MDS, Zurich, for Bioanalytics |
|
Kendle, CRO, Munich for
clinical development |
|
axxonis has started
a discovery research program with scientists from the Academy of Sciences
in Prague, CZ and the Free University Berlin to provide multiple drug
candidates against various drug targets to broaden our product portfolio
in the area of neurodegenerative and other disorders. |
|
Leopold-Franzens-Universität
Innsbruck, Austria. Prof. Dr. W. Poewe, Principal investigator, Lisuride
TTS. |
|
Universität Bochum,
Prof. Dr. Przuntek. |
|
Ivax, CR (formerly known
as Galena), Opava, Cz: producer of Lisuride |
|
IMEREM GmbH, CRO, Nuernberg,
Germany, for clinical development |
|
Conventis AG, CRO, Rostock,
Germany |
|
Fisher Clinical Services
CH GmbH, Switzerland |
|
| |
|
|
axxonis
Pharma AG, Schöneberger Straße 15, D-10963 Berlin,
Tel.: +49-30-2693429-0 , Fax: +49-30-2693429-22,
E-Mail: info@axxonis.com,
www.axxonis.com |
|
|
|
